Literature DB >> 8260252

Melanoma-associated antigens.

S Carrel1, D Rimoldi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8260252     DOI： 10.1016/0959-8049(93)90548-t

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  7 in total

1.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.

Authors:  M Wu; T J Hemesath; C M Takemoto; M A Horstmann; A G Wells; E R Price; D Z Fisher; D E Fisher
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

Review 2.  Recent advances in the treatment of malignant melanoma with gene therapy.

Authors:  E M Hersh; A T Stopeck
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

3.  Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.

Authors:  R King; K N Weilbaecher; G McGill; E Cooley; M Mihm; D E Fisher
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

4.  Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.

Authors:  M Q Mohammed; H D Abraha; R A Sherwood; K MacRae; S Retsas
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

5.  Renal capsular PEComa--a rare cause of surgically correctable renal hypertension.

Authors:  M Murugesan; E Courtauld; C Fisher; S Nathan
Journal:  Int Urol Nephrol       Date:  2007-02-22       Impact factor: 2.370

6.  MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.

Authors:  Jinyan Du; Arlo J Miller; Hans R Widlund; Martin A Horstmann; Sridhar Ramaswamy; David E Fisher
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

7.  High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.

Authors:  T J de Vries; D Trancikova; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.